Drug Name Acomplia

The bottom line is that if you use an HbA1c measurement as a screening test, you'll have a lot of false-negatives and some false-positives," said Mary Rhee, MD, Assistant Professor of Endocrinology at Emory University in Atlanta. And in this day and age when diabetes is a worsening public health epidemic not only in the U.S. but also around the world, we can't afford to end up with more cases of undiagnosed diabetes."
PROVENTIL HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

 

It is also used for treating hair loss and acne in women, and can be used as a topical medication for treatment of male baldness. It is commonly used to treat symptoms of polycystic ovary syndrome (PCOS) such as excess facial hair and acne. It can also cause gynecomastia in males and should never be given with potassium supplementation for fear of the development of hyperkalemia.
On 23 October 2008, the European Medicines Agency (EMEA) issued a press release stating its Committee for Medical Products for Human Use (CHMP) had concluded the benefits of Acomplia no longer outweighed its risks, and subsequently recommended the product be suspended from the UK market. Sanofi-Aventis later released a press statement stating the drug had been suspended. Approval of the drug was officially withdrawn by the EMEA on 16 January 2009.